The timeline of epigenetic drug discovery: from reality to dreams

The flexibility of the epigenome has generated an enticing argument to explore its reversion through pharmacological treatments as a strategy to ameliorate disease phenotypes. All three families of epigenetic proteins—readers, writers, and erasers—are druggable targets that can be addressed through...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganesan, A., Arimondo, Paola B., Rots, Marianne G., Jeronimo, Carmen, Berdasco, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888921/
https://www.ncbi.nlm.nih.gov/pubmed/31791394
http://dx.doi.org/10.1186/s13148-019-0776-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888921/
https://www.ncbi.nlm.nih.gov/pubmed/31791394
http://dx.doi.org/10.1186/s13148-019-0776-0

Ejemplares similares